Cholangiocarcinoma, Intrahepatic Clinical Trial
Official title:
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3) cisplatin and gemcitabine (CISGEM).
The study will have a Run-in portion and an Expansion portion. The Run-in portion will be used to evaluate the safety profile of the PEGCISGEM and PEGCISGEMATEZO treatments prior to evaluating the efficacy and safety of PEGCISGEM and PEGCISGEMATEZO treatments compared with CISGEM treatment in the Expansion portion of the study. Treatment in both portions of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04077983 -
Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04527679 -
Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Recruiting |
NCT04634058 -
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
|
Phase 2 | |
| Active, not recruiting |
NCT03951597 -
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Completed |
NCT03377179 -
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04361331 -
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Completed |
NCT04072250 -
Surgery for Recurrent Intrahepatic Cholangiocarcinoma
|
||
| Recruiting |
NCT05210322 -
Percutaneous Cholangiopancreatoscopy Registry
|
||
| Recruiting |
NCT04782804 -
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04264260 -
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
|
Phase 2 | |
| Recruiting |
NCT06140134 -
Liver Transplantation in Intrahepatic Cholangiocarcinoma
|
||
| Enrolling by invitation |
NCT04195503 -
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
|
N/A | |
| Recruiting |
NCT04506281 -
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
|
Phase 2 | |
| Recruiting |
NCT05124002 -
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
|
Phase 4 | |
| Terminated |
NCT03316222 -
Study of GNS561 in Patients With Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03405909 -
Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study
|
||
| Recruiting |
NCT06381648 -
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
|
||
| Available |
NCT03414489 -
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
|